Atossa Genetics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, yesterday FDA Aprroved Oral Endoxifen for breast cancer patient.
Endoxifen is an active metabolite of tamoxifen, which is an FDA-approved drug to prevent new as well as recurrent disease in breast cancer patients.
This good news bring positive impact to Atossa stocks.
Yesterday Atossa rose 395.26%, and this price movement is nothing if we compare with monthly range at past few years.
For long term investment, We have 24000% profit projection at 128.75 and 90000% maximum profit projection at 479
ATOSSA financial strength :
Piotroski F-Score: 3
Altman Z-Score: -7.74
Beneish M-Score: -4.78
Cash to debt : 0
Endoxifen is an active metabolite of tamoxifen, which is an FDA-approved drug to prevent new as well as recurrent disease in breast cancer patients.
This good news bring positive impact to Atossa stocks.
Yesterday Atossa rose 395.26%, and this price movement is nothing if we compare with monthly range at past few years.
For long term investment, We have 24000% profit projection at 128.75 and 90000% maximum profit projection at 479
ATOSSA financial strength :
Piotroski F-Score: 3
Altman Z-Score: -7.74
Beneish M-Score: -4.78
Cash to debt : 0
registrasi private class online untuk pembahasan pump/dump dibuka khusus untuk 1 siswa. Pembayaran sebesar $350 (+21jam materi pada real market) dilakukan setelah pelajaran pertama diterima.
keterangan lanjut, Whatsapp ke : +62895370949590
keterangan lanjut, Whatsapp ke : +62895370949590